Since the first use of cytotoxic chemicals to treat cancer, oncologists have been searching for ways to enhance efficacy without significantly increasing overall toxicity to patients. One of the methods attempted to improve the killing effect on tumor cells is the use of cytotoxic agents with potency at picomolar or lower levels (such as microtubule … Read more
History of ADC Drug Development Phase 1 (1906-1982), the concept of targeted therapy was proposed, and the technology took shape. Phase 2 (1983-2011), transition from clinical trials to commercialization, Mylotarg® was approved for market. Phase 3 (2012-present), explosive growth of ADC products. The five key elements of ADC drugs are target, antibody, linker, cytotoxic agent, … Read more
MQTT Packet Structure In the MQTT protocol, an MQTT packet consists of three parts: Fixed Header, Variable Header, and Payload. (1) Fixed Header. Present in all MQTT packets, indicating the packet type and group class identifier. (2) Variable Header. Present in some MQTT packets, the packet type determines whether the variable header exists and its … Read more
The development of ADC drugs has not been smooth sailing, with nearly 100 years of history since the concept of the “magic bullet” was proposed, but ultimately, the clouds have parted to reveal the moon. DS8201 has redefined ADC, but it is not the end of ADC drugs, rather a new beginning. A comprehensive understanding … Read more
ADC Field Blooms, new technologies evolve like a rolling tide, propelling biomedicine into high-speed mode. This is the best of times. As early as the early 20th century, Paul Ehrlich first proposed the concept of “magic bullets”; however, the first ADC drug, Mylotarg® (gemtuzumab ozogamicin), was not approved until nearly a century later. Every cloud … Read more
*For reference only by medical professionals The latest review reports that ADC drug resistance is related to antigen expression, ADC processing, and payload efficacy. Antibody-drug conjugates (ADC) are formed by the conjugation of specific targeting monoclonal antibodies and highly active cytotoxic drugs via linkers. With their unique pharmacological properties, ADC drugs exhibit powerful anti-tumor activity … Read more
1 Introduction Antibody-drug conjugates (ADC) are an emerging technology that selectively targets cancer cells to overcome the limitations of chemotherapy. ADC binds to antigens, especially those overexpressed on the surface of cancer cells, reducing side effects caused by nonspecific targeting and improving the therapeutic index. The ideal efficacy of an ADC is entirely dependent on … Read more
Since the first use of cytotoxic chemicals to treat cancer, oncologists have been searching for ways to improve efficacy without significantly increasing overall toxicity to patients. One of the methods attempted to enhance the killing effect on tumor cells is the use of cytotoxic agents with potency at picomolar or lower levels (such as microtubule … Read more